Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sami Aboumatar"'
Autor:
Robert T. Wechsler, James Wheless, Muhammad Zafar, Graham R. Huesmann, Marcelo Lancman, Eric Segal, Michael Chez, Sami Aboumatar, Anna Patten, Alejandro Salah, Manoj Malhotra
Publikováno v:
Epilepsia Open, Vol 7, Iss 2, Pp 293-305 (2022)
Abstract Objective To assess retention, dosing, efficacy, and safety of perampanel in a large cohort of patients with epilepsy during routine clinical care. Methods PROVE was a retrospective, non‐interventional Phase IV study (NCT03208660). Data we
Externí odkaz:
https://doaj.org/article/966bf4f538cd415fbac4e6152240276d
Autor:
James Wheless, Robert T. Wechsler, Marcelo Lancman, Sami Aboumatar, Anna Patten, Manoj Malhotra
Publikováno v:
Epilepsia Open, Vol 6, Iss 1, Pp 79-89 (2021)
Abstract Objective To assess the retention rate, efficacy, safety, and dosing of perampanel administered to patients with epilepsy during routine clinical care in the retrospective phase IV, PROVE Study (NCT03208660). Methods Exposure, efficacy, and
Externí odkaz:
https://doaj.org/article/efd1045dfef845daa2393e5f6b4ef8e1
Autor:
Sami Aboumatar, Victor Biton, William E. Rosenfeld, David G. Vossler, Gregory L. Krauss, Perminder Bhatia, Robert T. Wechsler, Bassel Abou-Khalil, Pavel Klein, Michael R. Sperling
Publikováno v:
Epilepsia. 62:3016-3028
Objective To report post hoc results on how adjustments to baseline antiseizure medications (ASMs) in a subset of study sites (10 US sites) from a long-term, open-label phase 3 study of adjunctive cenobamate affected tolerability, efficacy, and reten
Autor:
Bassel Abou-Khalil, David G. Vossler, Gregory L. Krauss, Louis Ferrari, Pavel Klein, Mindy Grall, Michael R. Sperling, Victor Biton, William E. Rosenfeld, Sami Aboumatar, Perminder Bhatia, Robert T. Wechsler
Publikováno v:
Epilepsia. 62:3005-3015
Objective To report long-term post hoc efficacy and safety data from 10 US study sites from an open-label Phase 3 study of adjunctive cenobamate (NCT02535091). Methods Patients with uncontrolled focal seizures taking stable doses of 1-3 antiseizure m
Publikováno v:
Clinical Neurology and Neurosurgery. 225:107552
Autor:
Anna Patten, Marcelo Lancman, Sami Aboumatar, Manoj Malhotra, James W. Wheless, Robert T. Wechsler
Publikováno v:
Epilepsia Open, Vol 6, Iss 1, Pp 79-89 (2021)
Epilepsia Open
Epilepsia Open
Objective To assess the retention rate, efficacy, safety, and dosing of perampanel administered to patients with epilepsy during routine clinical care in the retrospective phase IV, PROVE Study (NCT03208660). Methods Exposure, efficacy, and safety da
Publikováno v:
Epilepsy research. 186
This post hoc analysis (n = 240) of a subset of study sites (10 eligible US sites) from an open-label phase 3 study assessed whether baseline seizure frequency (3 seizures/28 days vs ≥3 seizures/28 days) impacted mean cenobamate dose required to ac
Autor:
Bassel, Abou-Khalil, Sami, Aboumatar, Pavel, Klein, Gregory L, Krauss, Michael R, Sperling, William E, Rosenfeld
Publikováno v:
Epilepsy Research. 184:106952
This post hoc analysis of 10 US study sites from a long-term open-label phase 3 study of adjunctive cenobamate evaluated the efficacy of cenobamate in patients with prior epilepsy-related surgery.Patients with uncontrolled focal seizures despite taki
Autor:
Pavel Klein, Sami Aboumatar, Christian Brandt, Fang Dong, Gregory L. Krauss, Sarah Mizne, Juan Carlos Sánchez-Álvarez, Bernhard J. Steinhoff, Vicente Villanueva
Publikováno v:
Neurology.
Background and ObjectivesTo evaluate long-term efficacy (percent seizure frequency reduction and responder rates), safety, and tolerability of adjunctive cenobamate (CNB) in an open-label extension (OLE) of the randomized, double-blind, placebo-contr
Autor:
Robert T. Wechsler, William E. Rosenfeld, Michael A. Gelfand, Marc Kamin, Jonathan J. Halford, Sami Aboumatar, Leona Borchert, David G. Vossler, Michael R. Sperling, Gregory L. Krauss, Pavel Klein
Publikováno v:
Epilepsia
Objective During the development of cenobamate, an antiseizure medication (ASM) for focal seizures, three cases of drug reaction with eosinophilia and systemic symptoms (DRESS) occurred. To mitigate the rate of DRESS, a start‐low, go‐slow approac